Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA vaccine plus PD-1 antibody and targeted therapy in advanced hepatocellular carcinoma after first-line failure
ChiCTR2600126160Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of PCV-NEO-ONC-RNA in hepatocellular carcinoma (HCC) (5 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Progression-Free Survival and Objective Response Rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
PCV-NEO-ONC-RNA
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600126160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126160.